134 related articles for article (PubMed ID: 37312616)
1. Associations between higher plasma ferritin and hepcidin levels with liver stiffness in patients with type 2 diabetes: An exploratory study.
Mantovani A; Csermely A; Castagna A; Antinori E; Danese E; Zusi C; Sani E; Ravaioli F; Colecchia A; Maffeis C; Valenti L; Girelli D; Targher G
Liver Int; 2023 Nov; 43(11):2434-2444. PubMed ID: 37312616
[TBL] [Abstract][Full Text] [Related]
2. Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes.
Mantovani A; Turino T; Lando MG; Gjini K; Byrne CD; Zusi C; Ravaioli F; Colecchia A; Maffeis C; Salvagno G; Lippi G; Bonora E; Targher G
Diabetes Metab; 2020 Sep; 46(4):296-303. PubMed ID: 31786361
[TBL] [Abstract][Full Text] [Related]
3. Association between lower plasma adiponectin levels and higher liver stiffness in type 2 diabetic individuals with nonalcoholic fatty liver disease: an observational cross-sectional study.
Mantovani A; Zusi C; Csermely A; Salvagno GL; Colecchia A; Lippi G; Maffeis C; Targher G
Hormones (Athens); 2022 Sep; 21(3):477-486. PubMed ID: 35831700
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Adverse Effect of Liver Stiffness on Glycaemic Control in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease: A Pilot Study.
Mantovani A; Taverna A; Cappelli D; Beatrice G; Csermely A; Sani E; Byrne CD; Targher G
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293337
[TBL] [Abstract][Full Text] [Related]
5. Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes: Evidence from the CORDIAL cohort study.
Alfadda AA; Sherbeeni SM; Alqutub AN; Aldosary AS; Aldaghri NM; Taylor-Robinson SD; Alqahtani SA; Gul R; Almaghamsi AM
Saudi J Gastroenterol; 2022; 28(6):426-433. PubMed ID: 35645140
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis.
Sagara M; Iijima T; Kase M; Kato K; Sakurai S; Tomaru T; Jojima T; Usui I; Aso Y
J Diabetes Complications; 2021 May; 35(5):107885. PubMed ID: 33602617
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population.
Petta S; Di Marco V; Pipitone RM; Grimaudo S; Buscemi C; Craxì A; Buscemi S
Liver Int; 2018 Nov; 38(11):2060-2068. PubMed ID: 29577560
[TBL] [Abstract][Full Text] [Related]
8. Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.
Sobhonslidsuk A; Pulsombat A; Kaewdoung P; Petraksa S
Asian Pac J Cancer Prev; 2015; 16(5):1789-94. PubMed ID: 25773826
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of controlled attenuation parameter and liver stiffness measurement for detecting increased arterial stiffness in asymptomatic populations in China.
Yu XY; Song XX; Tong YL; Wu LY; Song ZY
Medicine (Baltimore); 2020 Nov; 99(48):e23360. PubMed ID: 33235107
[TBL] [Abstract][Full Text] [Related]
10. [Characteristic analysis of patients with type 2 diabetes mellitus combined with advanced stage chronic liver disease: a community population-based cross-sectional study in Heping District, Shenyang City (CHESS-LN 2101)].
Lyu C; Fu WL; Gu Y; Wang LS; Wang XM; Liu X; Qian JM; Tao Z; Chen Y; Liu C; He RL; Guan X; Wang Y; Wang Y; Qi XL
Zhonghua Gan Zang Bing Za Zhi; 2022 Nov; 30(11):1194-1200. PubMed ID: 36891697
[No Abstract] [Full Text] [Related]
11. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
[TBL] [Abstract][Full Text] [Related]
12. Metabolic dysfunction-associated steatotic liver disease-related hepatic fibrosis increases risk of insulin resistance, type 2 diabetes, and chronic kidney disease.
Zhang W; Song WJ; Chen W; Pan Z; Zhang J; Fan L; Li J
Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):802-810. PubMed ID: 38526946
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y
Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600
[TBL] [Abstract][Full Text] [Related]
14. Association of fetuin B with markers of liver fibrosis in nonalcoholic fatty liver disease.
Ebert T; Linder N; Schaudinn A; Busse H; Berger J; Lichtinghagen R; Keim V; Wiegand J; Karlas T
Endocrine; 2017 Nov; 58(2):246-252. PubMed ID: 28914407
[TBL] [Abstract][Full Text] [Related]
15. Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes.
Mantovani A; Sani E; Fassio A; Colecchia A; Viapiana O; Gatti D; Idolazzi L; Rossini M; Salvagno G; Lippi G; Zoppini G; Byrne CD; Bonora E; Targher G
Diabetes Metab; 2019 Sep; 45(4):347-355. PubMed ID: 30315891
[TBL] [Abstract][Full Text] [Related]
16. Liver fibrosis by FibroScan
Lombardi R; Airaghi L; Targher G; Serviddio G; Maffi G; Mantovani A; Maffeis C; Colecchia A; Villani R; Rinaldi L; Orsi E; Pisano G; Adinolfi LE; Fargion S; Fracanzani AL
Liver Int; 2020 Feb; 40(2):347-354. PubMed ID: 31612634
[TBL] [Abstract][Full Text] [Related]
17. Advanced liver fibrosis predicts heart failure and hospitalizations in people with type 2 diabetes: A prospective cohort study from Hong Kong Diabetes Register.
Kong AP; Lau ES; O CK; Luk AO; Yip TC; Chow EY; Kwok R; Lee HW; Wong GL; Ma RC; Chan HL; Wong VW; Chan JC
Diabetes Res Clin Pract; 2023 Aug; 202():110825. PubMed ID: 37442241
[TBL] [Abstract][Full Text] [Related]
18. Visceral Adipose Tissue and Non-alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes.
Nobarani S; Alaei-Shahmiri F; Aghili R; Malek M; Poustchi H; Lahouti M; Khamseh ME
Dig Dis Sci; 2022 Apr; 67(4):1389-1398. PubMed ID: 33788095
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease.
Shima T; Sakai K; Oya H; Katayama T; Mitsumoto Y; Mizuno M; Kanbara Y; Okanoue T
J Gastroenterol; 2020 Jan; 55(1):100-112. PubMed ID: 31538241
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
